N7-Methylguanosine Genes Related Prognostic Biomarker in Hepatocellular Carcinoma

Overview

Journal Front Genet

Date 2022 Jun 23

PMID 35734429

Authors

Parbatraj Regmi

Zhi-Qiang He

Thongher Lia

Aliza Paudyal

Fu-Yu Li

Affiliations

Soon will be listed here.

Abstract

About 90% of liver cancer-related deaths are caused by hepatocellular carcinoma (HCC). N7-methylguanosine (m7G) modification is associated with the biological process and regulation of various diseases. To the best of our knowledge, its role in the pathogenesis and prognosis of HCC has not been thoroughly investigated. To identify N7-methylguanosine (m7G) related prognostic biomarkers in HCC. Furthermore, we also studied the association of m7G-related prognostic gene signature with immune infiltration in HCC. The TCGA datasets were used as a training and GEO dataset "GSE76427" for validation of the results. Statistical analyses were performed using the R statistical software version 4.1.2. Functional enrichment analysis identified some pathogenesis related to HCC. We identified 3 m7G-related genes (CDK1, ANO1, and PDGFRA) as prognostic biomarkers for HCC. A risk score was calculated from these 3 prognostic m7G-related genes which showed the high-risk group had a significantly poorer prognosis than the low-risk group in both training and validation datasets. The 3- and 5-years overall survival was predicted better with the risk score than the ideal model in the entire cohort in the predictive nomogram. Furthermore, immune checkpoint genes like CTLA4, HAVCR2, LAG3, and TIGT were expressed significantly higher in the high-risk group and the chemotherapy sensitivity analysis showed that the high-risk groups were responsive to sorafenib treatment. These 3 m7G genes related signature model can be used as prognostic biomarkers in HCC and a guide for immunotherapy and chemotherapy response. Future clinical study on this biomarker model is required to verify its clinical implications.

Citing Articles

Telomere Maintenance-Related Genes are Essential for Prognosis in Breast Cancer.

Huang W, Wang W, Dong T Breast Cancer (Dove Med Press). 2025; 17:225-239.

PMID: 40028272 PMC: 11869761. DOI: 10.2147/BCTT.S506783.

Emerging influence of RNA post-transcriptional modifications in the synovial homeostasis of rheumatoid arthritis.

Fatima M, Huang F, Fu X Front Immunol. 2024; 15:1494873.

PMID: 39717780 PMC: 11663879. DOI: 10.3389/fimmu.2024.1494873.

RNA modifications in cancer immune therapy: regulators of immune cells and immune checkpoints.

Qin X, Liu H, Zhang Q, Che Y, Lei T, Tang F Front Immunol. 2024; 15:1463847.

PMID: 39372415 PMC: 11449722. DOI: 10.3389/fimmu.2024.1463847.

The role of anoctamin 1 in liver disease.

Li X, Wang Y, Zhang L, Yao S, Liu Q, Jin H J Cell Mol Med. 2024; 28(9):e18320.

PMID: 38685684 PMC: 11058335. DOI: 10.1111/jcmm.18320.

mA regulator-mediated methylation modification patterns correlated with autophagy to predict the prognosis of hepatocellular carcinoma.

Wu Y, Li L, Wang L, Zhang S, Zeng Z, Lu J BMC Cancer. 2024; 24(1):506.

PMID: 38649860 PMC: 11034060. DOI: 10.1186/s12885-024-12235-4.

References

Yu J, Kim J, Kim J, Choi S, Lee K, Lee J . Platelet-derived growth factor receptor α in hepatocellular carcinoma is a prognostic marker independent of underlying liver cirrhosis. Oncotarget. 2017; 8(24):39534-39546. PMC: 5503630. DOI: 10.18632/oncotarget.17134. View

Yang W, Pan Y, You C . CDK1, CCNB1, CDC20, BUB1, MAD2L1, MCM3, BUB1B, MCM2, and RFC4 May Be Potential Therapeutic Targets for Hepatocellular Carcinoma Using Integrated Bioinformatic Analysis. Biomed Res Int. 2019; 2019:1245072. PMC: 6815605. DOI: 10.1155/2019/1245072. View

Qiang R, Zhao Z, Tang L, Wang Q, Wang Y, Huang Q . Identification of 5 Hub Genes Related to the Early Diagnosis, Tumour Stage, and Poor Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma by Bioinformatics Analysis. Comput Math Methods Med. 2021; 2021:9991255. PMC: 8483908. DOI: 10.1155/2021/9991255. View

Han R, Feng P, Pang J, Zou D, Li X, Geng C . A Novel HCC Prognosis Predictor EEF1E1 Is Related to Immune Infiltration and May Be Involved in EEF1E1/ATM/p53 Signaling. Front Oncol. 2021; 11:700972. PMC: 8285289. DOI: 10.3389/fonc.2021.700972. View

Rizzo A, Ricci A . Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond. Expert Opin Investig Drugs. 2021; 31(6):549-555. DOI: 10.1080/13543784.2022.2008354. View

Chen Z, Zhu W, Zhu S, Sun K, Liao J, Liu H . METTL1 promotes hepatocarcinogenesis via m G tRNA modification-dependent translation control. Clin Transl Med. 2021; 11(12):e661. PMC: 8666584. DOI: 10.1002/ctm2.661. View

Trimouille A, Lasseaux E, Barat P, Deiller C, Drunat S, Rooryck C . Further delineation of the phenotype caused by biallelic variants in the WDR4 gene. Clin Genet. 2017; 93(2):374-377. DOI: 10.1111/cge.13074. View

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

Song B, Tang Y, Chen K, Wei Z, Rong R, Lu Z . m7GHub: deciphering the location, regulation and pathogenesis of internal mRNA N7-methylguanosine (m7G) sites in human. Bioinformatics. 2020; 36(11):3528-3536. DOI: 10.1093/bioinformatics/btaa178. View

10.

Lopes Pereira P, Magnol L, Sahun I, Brault V, Duchon A, Prandini P . A new mouse model for the trisomy of the Abcg1-U2af1 region reveals the complexity of the combinatorial genetic code of down syndrome. Hum Mol Genet. 2009; 18(24):4756-69. PMC: 2778371. DOI: 10.1093/hmg/ddp438. View

11.

Min S, Lee Y, Hong J, Park T, Woo H, Kwon S . MRPS31 loss is a key driver of mitochondrial deregulation and hepatocellular carcinoma aggressiveness. Cell Death Dis. 2021; 12(11):1076. PMC: 8589861. DOI: 10.1038/s41419-021-04370-8. View

12.

Luo Y, Fang L, Yu H, Zhang J, Lin X, Liu X . p53 haploinsufficiency and increased mTOR signalling define a subset of aggressive hepatocellular carcinoma. J Hepatol. 2020; 74(1):96-108. DOI: 10.1016/j.jhep.2020.07.036. View

13.

Li J, Xing J, Yang Y, Liu J, Wang W, Xia Y . Adjuvant I-metuximab for hepatocellular carcinoma after liver resection: a randomised, controlled, multicentre, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2020; 5(6):548-560. DOI: 10.1016/S2468-1253(19)30422-4. View

14.

Kovacs M, Nagy P, Pak G, Feher J . [Gastrointestinal stromal tumors (GISTs): clinical and pathological features]. Orv Hetil. 2005; 146(26):1375-81. View

15.

Han S, Qi J, Fang K, Wang H, Tang Y, Wu D . Characterization of m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration in acute myeloid leukemia. Cancer Med. 2022; 11(5):1413-1426. PMC: 8894699. DOI: 10.1002/cam4.4531. View

16.

Bruix J, Reig M, Sherman M . Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. Gastroenterology. 2016; 150(4):835-53. DOI: 10.1053/j.gastro.2015.12.041. View

17.

Guo M, Qi F, Rao Q, Sun J, Du X, Qi Z . Serum LAG-3 Predicts Outcome and Treatment Response in Hepatocellular Carcinoma Patients With Transarterial Chemoembolization. Front Immunol. 2021; 12:754961. PMC: 8530014. DOI: 10.3389/fimmu.2021.754961. View

18.

Ma J, Han H, Huang Y, Yang C, Zheng S, Cai T . METTL1/WDR4-mediated mG tRNA modifications and mG codon usage promote mRNA translation and lung cancer progression. Mol Ther. 2021; 29(12):3422-3435. PMC: 8636169. DOI: 10.1016/j.ymthe.2021.08.005. View

19.

Fitzmaurice C, Allen C, Barber R, Barregard L, Bhutta Z, Brenner H . Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2016; 3(4):524-548. PMC: 6103527. DOI: 10.1001/jamaoncol.2016.5688. View

20.

Barbieri I, Tzelepis K, Pandolfini L, Shi J, Millan-Zambrano G, Robson S . Promoter-bound METTL3 maintains myeloid leukaemia by mA-dependent translation control. Nature. 2017; 552(7683):126-131. PMC: 6217924. DOI: 10.1038/nature24678. View